Arcus Biosciences Announces New Employment Inducement Grants
2024年8月27日 - 5:35AM
ビジネスワイヤ(英語)
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer, today
announced that the Compensation Committee of the Company’s Board of
Directors granted three new employees options to purchase a total
of 21,100 shares of the Company’s common stock at an exercise price
per share of $18.01, which was the closing price on August 23,
2024, and restricted stock units to acquire a total of 10,550
shares of the Company’s common stock. The equity awards were
granted pursuant to the Company’s 2020 Inducement Plan, which was
approved by the Company’s Board of Directors in January 2020
pursuant to the “inducement exception” under NYSE Listed Company
Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
collaborators, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor), HIF-2a, CD39, and AXL. For more information
about Arcus Biosciences’ clinical and preclinical programs, please
visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240826881267/en/
Investor Inquiries: Pia
Eaves VP of Investor Relations & Strategy (617) 459-2006
peaves@arcusbio.com
Media Inquiries: Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
過去 株価チャート
から 11 2024 まで 12 2024
Arcus Biosciences (NYSE:RCUS)
過去 株価チャート
から 12 2023 まで 12 2024